Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 40, Issue 7, Pages 1425-1433Publisher
WILEY
DOI: 10.1002/hed.25112
Keywords
Asian; cisplatin; nasopharyngeal carcinoma; ototoxicity; radiotherapy
Categories
Funding
- Biomedical Research Council of the Agency for Science, Technology, and Research of Singapore (Strategic Positioning Funds)
- National University of Singapore
- Clinician Scientist New Investigator Grant from the National Medical Research Council of Singapore
Ask authors/readers for more resources
Background: The purpose of this study was to characterize the clinical course of hearing loss in patients with nasopharyngeal carcinoma (NPC) and the clinical factors affecting its severity. Methods: The time course of hearing loss in patients with NPC was assessed using threshold shift from baseline and Common Terminology Criteria for Adverse Events (CTCAE) grade. Results: In the chemoradiotherapy (CRT) groups, the threshold shift was significantly higher from 3 months at 4 kHz (P52.3031029, concurrent CRT only) but not within 2 years posttreatment in the radiotherapy (RT) group. The CRT groups had worse CTCAE grades than the RT group (percentage of latest CTCAE grade similar to 1: 64.9% vs 29.0%, respectively). Cumulative cisplatin dose and cochlear RT dose significantly affects threshold shifts, especially at high frequencies. Conclusion: Although cisplatin led to high frequency hearing impairment from about 3 months posttreatment, RT conferred no significant hearing impairment in the first 2 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available